Compare BIDU & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIDU | INSM |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9B | 41.2B |
| IPO Year | 2005 | 2000 |
| Metric | BIDU | INSM |
|---|---|---|
| Price | $124.85 | $177.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 21 |
| Target Price | $144.23 | ★ $185.84 |
| AVG Volume (30 Days) | 2.2M | ★ 3.7M |
| Earning Date | 11-18-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.25 | N/A |
| Revenue | ★ $18,325,514,127.00 | $447,022,000.00 |
| Revenue This Year | N/A | $43.95 |
| Revenue Next Year | $4.78 | $130.35 |
| P/E Ratio | $38.42 | ★ N/A |
| Revenue Growth | N/A | ★ 30.34 |
| 52 Week Low | $74.71 | $60.40 |
| 52 Week High | $149.51 | $212.75 |
| Indicator | BIDU | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 54.26 | 40.56 |
| Support Level | $121.80 | $172.65 |
| Resistance Level | $125.37 | $179.33 |
| Average True Range (ATR) | 2.73 | 7.15 |
| MACD | 0.25 | -3.04 |
| Stochastic Oscillator | 50.70 | 37.18 |
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 70% of core revenue from online marketing services from its search engine in 2024. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.